Af­ter sting­ing FDA set­back, Glax­o­SmithK­line's Vi­iV fi­nal­ly notch­es US ap­proval for long-act­ing HIV in­jec­tion

Glax­o­SmithK­line’s HIV unit Vi­iV was dealt a sting­ing loss back in late 2019 when the FDA slammed the brakes on its ap­pli­ca­tion for a once-month­ly in­jec­tion based on man­u­fac­tur­ing is­sues. Now, with that road­block in the rearview, Vi­iV has fi­nal­ly made good on its promise to change the HIV game.

The FDA on Thurs­day ap­proved Vi­iV’s Cabe­nu­va (cabote­gravir and rilpivirine) as a long act­ing, once-month­ly ther­a­py for HIV-pos­i­tive adults who are vi­ro­log­i­cal­ly sup­pressed and on a sta­ble an­tivi­ral reg­i­men.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER